Liraglutide Injection shortage
Liraglutide Injection is currently listed in shortage by the FDA. The FDA lists 11 affected products. The reported reason: Delay in shipping of the drug; Discontinuation of the manufacture of the drug. This page was last refreshed from FDA data on Sep 25, 2026.
Novo Nordisk is discontinuing liraglutide injection, with the change expected to become permanent in January 2027. The 6 mg/mL strength is still listed as available from other sources, including Saxenda and Victoza branded products.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Liraglutide Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Sep 22, 2026Currently in shortage11 of 11 products affected.
-
Sep 18, 2026FDA refreshed this shortage record2 products updated.
-
Aug 27, 2026FDA refreshed this shortage record2 products updated.
-
Aug 25, 2026FDA refreshed this shortage record1 product updated.
-
Aug 25, 2026More presentations reported1 more product added to the shortage.
-
May 14, 2026FDA refreshed this shortage record1 product updated.
-
May 14, 2026More presentations reported1 more product added to the shortage.
-
Jul 18, 2023First reported to the FDA9 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02) | — | Available | — | — |
| Current | Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03) | — | Available | — | — |
Manufacturer: Meitheal Pharmaceuticals, Inc. 📞 844-824-8426 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85) | — | Available | — | — |
| Current | Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84) | — | Available | — | — |
Manufacturer: Novo Nordisk, Inc. 📞 833-493-4689 6 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20) | — | Available | Distributed by Teva | — |
| Current | Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12) | — | Limited Availability | Estimated shortage duration: TBD | Delay in shipping of the drug |
| Current | Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13) | — | Limited Availability | Estimated shortage duration: TBD | Delay in shipping of the drug |
| Current | Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15) | — | Limited Availability | Product will be available until discontinuation in January 2027 | Discontinuation of the manufacture of the drug |
| Current | Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22) | — | Available | Distributed by Teva | — |
| To Be Discontinued | Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15) | — | — | Product will be available until discontinuation in January 2027; Discontinuation of the manufacture of the drug | — |
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 888-838-2872 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46) | — | — | Discontinuation of the manufacture of the drug | — |
These rows are manufacturer reports to the FDA for Liraglutide Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Liraglutide Injection? options further down this page.
Why is Liraglutide Injection in shortage?
There are actually two separate things happening with liraglutide 6 mg/1 mL from Novo Nordisk right now. First, their Victoza brand (two specific package sizes) is running short because of a delay in getting shipments out — they haven't given a firm timeline yet for when that will be resolved. Second, their Saxenda brand is being permanently stopped — Novo Nordisk has said it will continue to be available until it's discontinued in January 2027, so there is still some time before it goes away completely. Teva is also permanently stopping their version of liraglutide 6 mg/1 mL, though no wind-down date was shared for that one.
It's worth knowing that this report reflects only what these specific manufacturers filed with the FDA. Other companies — including Meitheal and Hikma — are reporting their liraglutide 6 mg/1 mL products as currently available.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Liraglutide Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Liraglutide Injection?
Liraglutide injection is currently on the FDA shortage list, but supply is holding fairly steady. The single strength, 6 mg/1 mL, still has an available source — in fact, no strength is marked as having no supply right now.
Here is how it looks: the shortage has been ongoing for over a year, and the reported reasons include a shipping delay from one supplier and a planned discontinuation of certain products. Even so, 3 of the 4 manufacturers on this record still report supply of the 6 mg/1 mL strength. A few branded versions (such as Victoza and Saxenda) are listed as limited, and Saxenda is noted to remain available only until a planned discontinuation in January 2027 — meaning that particular product may not continue long-term.
What you can do:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to order the 6 mg/1 mL strength — since it still has supply, they can check wholesalers and other manufacturers for you.
- The same medicine (liraglutide 6 mg/mL) is made by several companies; your pharmacy may be able to source one, though it may not be in local stock.
- If you take a specific brand facing discontinuation, talk with your prescriber or pharmacist about your options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This national data may not match your local pharmacy's actual stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Liraglutide Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Liraglutide Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Saxenda | LIRAGLUTIDE 6 mg/mL | Injection, Solution · Subcutaneous | Novo Nordisk Pharmaceutical Industries, LP | 00169-2800-90 |
| Victoza | LIRAGLUTIDE 6 mg/mL | Injection · Subcutaneous | Novo Nordisk | 00169-4060-90 |
| Liraglutide | LIRAGLUTIDE 6 mg/mL | Injection · Subcutaneous | A-S Medication Solutions | 50090-7501-00 |
| Liraglutide | LIRAGLUTIDE 6 mg/mL | Injection, Solution · Subcutaneous | Cipla USA Inc. | 69097-0910-55 |
| Liraglutide | LIRAGLUTIDE 6 mg/mL | Injection · Subcutaneous | Biocon Pharma Inc. | 70377-0094-52 |
| Liraglutide | LIRAGLUTIDE 6 mg/mL | Injection, Solution · Subcutaneous | Biocon Pharma Inc. | 70377-0095-52 |
| Liraglutide | LIRAGLUTIDE 6 mg/mL | Injection · Subcutaneous | Lupin Pharmaceuticals, Inc. | 70748-0346-02 |
| Liraglutide | LIRAGLUTIDE 6 mg/mL | Injection · Subcutaneous | NorthStar Rx LLC | 72603-0745-02 |
Therapeutic equivalents & pricing 21 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Liraglutide 6 mg/mL | Meitheal | 3 syringes | $30.632 | AP1 | Availability likely |
| Liraglutide 6 mg/mL | Hikma | 3 syringes | $30.632 | AP1 | Availability likely |
| Liraglutide 6 mg/mL | Hikma | 2 syringes | $31.406 | AP1 | Availability likely |
| Liraglutide 6 mg/mL | Teva | 2 syringes | $31.406 | AP1 | Availability likely |
| Liraglutide 6 mg/mL | Cipla | 2 syringes | $31.406 | AP1 | Availability likely |
| Liraglutide 6 mg/mL | Biocon | 2 syringes | $31.406 | AP1 | Availability likely |
| Liraglutide 6 mg/mL | Lupin | 2 syringes | $31.406 | AP1 | Availability likely |
| Liraglutide 6 mg/mL | NorthStar | 2 syringes | $31.406 | AP1 | Availability likely |
| Liraglutide 6 mg/mL | Meitheal | 2 syringes | $31.406 | AP1 | Availability likely |
| liraglutide 6 mg/mL | Cipla | 5 syringes | $49.248 | AP2 | Availability likely |
| Liraglutide 6 mg/mL | Teva | 5 syringes | $49.248 | AP2 | Availability likely |
| Saxenda 6 mg/mL | Novo | 5 syringes | $87.126 | AP2 | Availability likely |
| Victoza 6 mg/mL | Novo | 2 syringes | $87.748 | AP1 | Availability likely |
| Liraglutide 18 mg/3mL | Hybio | 3 ml | — | AP1 | FDA listed |
| Victoza 6 mg/mL | A-S | 3 syringes | — | AP1 | FDA listed |
| Victoza 6 mg/mL | A-S | 3 syringes | — | AP1 | FDA listed |
| Liraglutide 6 mg/mL | A-S | 3 syringes | — | AP1 | FDA listed |
| Liraglutide 6 mg/mL | Orbicular | 3 syringes | — | AP1 | FDA listed |
| liraglutide 6 mg/mL | Orbicular | 3 syringes | — | AP2 | FDA listed |
| Saxenda 6 mg/mL | A-S | 5 syringes | — | AP2 | FDA listed |
| Liraglutide 6 mg/mL | Biocon | 3 syringes | — | AP2 | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Liraglutide Injection — that fall in the same broad treatment class (antihypergly,incretin mimetic(glp-1 recep.agonist)) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other endocrinology/metabolism shortages
Liraglutide Injection shortage FAQs
Is Liraglutide Injection in shortage?
Why is Liraglutide Injection in shortage?
Which products are affected?
When will Liraglutide Injection be available again?
Can I still get Liraglutide somewhere?
What should I do if I take Liraglutide Injection?
Still have a question about the Liraglutide Injection shortage?
Ask a pharmacist about this shortage →View Liraglutide Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.